Rome

• Phase II study evaluating Holmium-166 TARE followed by maIntenance Therapy in liver limited unresectable colorectal cancer patients after fi … Ended
  2023-505356-22-00 4 2024-03-13 Liver limited unresectable colorectal cancer
• A clinical study of MK-6194 for the treatment of Systemic Lupus Erythematosus (SLE) (MK-6194-006) Ended
  2023-505520-61-00 10 2024-03-11 Systemic Lupus Erythematosus
• A study to learn if baxdrostat works at reducing blood pressure and is safe in people with high blood pressure Ended
  2023-505499-32-00 5 2024-03-08 Uncontrolled hypertension (uTHN) defined as blood pressure that remain
• A study to learn how well the study treatment finerenone works and how safe it is in people with long-term decrease in the kidneys’ ability … Ended
  2022-503024-27-00 5 2024-02-27 Chronic kidney disease associated with type 1 diabetes mellitus
• A Study to Investigate Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age with Moder … Ended
  2022-502183-20-00 5 2024-02-26 Moderately to Severely Active Ulcerative Colitis
• GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer Ended
  2022-502453-33-00 4 2024-02-26 Advanced Endometrial Cancer
• A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended
  2022-502461-23-00 5 2024-02-15 Prurigo Nodularis
• "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended
  2023-505543-39-00 5 2024-02-12 Chronic Obstructive Pulmonary Disease (COPD)
• Open-label study to evaluate metreleptin in children under 6 years of age with generalised lipodystrophy Ended
  2022-501781-22-00 5 2024-02-09 Generalised lipodystrophy
• A research study to see how well new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar … Ended
  2022-502484-38-00 5 2024-02-07 Type 2 diabetes
• A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with … Ended
  2022-501310-57-00 4 2024-02-05 Endometriosis related pain
• A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo … Ended
  2023-505910-10-00 4 2024-01-23 Relapsed or Refractory High-Risk Myelodysplastic Syndrome
• MK-0616-013 Ended
  2022-502777-42-01 5 2024-01-16 Hypercholesterolemia
• (VELA) Study of BLU-222 in Advanced Solid Tumors Ended
  2022-502528-29-00 7 2024-01-09 HR+ Breast Cancer CCNE1 Amplification HER2-negative Breast Cancer Adva
• A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibul … Ended
  2023-505487-11-00 5 2023-12-21 Actinic Keratosis on the Face or Scalp
• PH2a, VH3739937 Proof-Of-Concept in TN HIV-1 Infected Adults Ended
  2023-505780-37-00 4 2023-12-21 HIV Infections
• A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis Ended
  2023-503315-15-00 4 2023-12-20 Thrombolysis of symptomatic proximal vein thrombosis
• Proof of concept treatment study of orally administered VH4004280 or VH4011499 in HIV-1 infected adults Ended
  2023-505350-18-00 4 2023-12-15 HIV Infections
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the … Ended
  2023-503614-80-00 5 2023-12-14 Pulmonary Arterial Hypertension
• Extension Study to Assess Batoclimab in Participants with TED. Ended
  2024-512650-21-00 5 2023-12-13 Thyroid Eye Disease (TED)
• A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release … Ended
  2023-505296-72-00 4 2023-12-12 Idiopathic Pulmonary Fibrosis (IPF)
• A study to evaluate the efficacy, safety, participant choice and preference of an oral once-daily regimen or a long-acting injectable regim … Ended
  2023-503893-19-00 5 2023-12-06 HIV-1 infection
• Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended
  2023-504673-20-00 4 2023-12-06 Ulcerative Colitis
• Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants with Moderate to Severe Ulcerative Colitis Ended
  2022-503005-38-00 4 2023-12-04 Ulcerative Colitis

Showing 1,753–1,776 of 2,096 trials